MacLean S. Hall

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

J. Mulé, J. Teer, S. Yoder, 2023, Journal for ImmunoTherapy of Cancer.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

V. Sondak, K. Flaherty, K. Smalley, 2010, British Journal of Cancer.

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Daohai Yu, J. Weber, A. Sarnaik, 2012, Journal of Translational Medicine.

Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.

John E. Mullinax, R. Gonzalez, J. Mulé, 2021, Journal of immunotherapy.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

John E. Mullinax, V. Sondak, J. Mulé, 2018, Front. Oncol..

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

Shari Pilon-Thomas, M. Malafa, A. Sarnaik, 2016, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.